Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AK002 in healthy participants
NCT02859701Phase 1Completed
- Sponsor
- Allakos Inc.
- Start
- Aug 2016
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in eosinophilic gastritis (EG), eosinophilic duodenitis (EoD) and systemic mastocytosis (SM) comparing AK002 with Placebo (2 arms). Primary endpoint: Incidence, nature and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Aug 2016; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic gastritis (EG)eosinophilic duodenitis (EoD)systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT02859701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859701.